Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy

BACKGROUND: Patients with undifferentiated nasopharyngeal carcinoma (NPC) have elevated serum levels of CYFRA 21-1 (CYFRA), ferritin, and beta-2-microglobulin (beta2M) compared with healthy control individuals. The prognostic value of these markers has never been validated prospectively. METHODS: Paired serum samples from 160 patients with newly diagnosed, nonmetastatic, undifferentiated NPC were collected before radiotherapy (RT) and at 4-6 weeks after the completion of RT. Pre-RT and post-RT levels of serum CYFRA, ferritin, and beta2M were analyzed and correlated with overall survival (OS), progression-free survival (PFS), time to locoregional recurrence, (TLR) and time to distant recurrence (TDR). The results of pre-RT and post-RT plasma Epstein-Barr virus (EBV) DNA levels available from a previous study were included in a Cox regression model together with age, tumor (T) classification, and lymph node (N) classification. RESULTS: Sixty percent of patients had International Union Against Cancer Stage III-IV disease. At a median follow-up of 116 weeks (range, 37-239 weeks), 38 patients had disease progression. On multivariate analysis, pre-RT CYFRA and post-RT EBV DNA levels were independent predictors of poor OS, post-RT EBV DNA level and N classification predicted poor PFS and TDR; and only T classification predicted TLR. Patients who had pre-RT CYFRA levels > or = 1.5 U/mL were more likely to die (hazard ratio, 1.18; 95% confidence interval, 1.10-1.26) compared with patients who had pre-RT CYFRA levels < 1.5 U/mL. There were no associations between age, post-RT CYFRA levels and pre-RT or post-RT serum ferritin and beta2M levels, and the survival and recurrence rates on multivariate analysis. CONCLUSIONS: Serum CYFRA levels taken before RT predicted reduced survival in patients with nonmetastatic, undifferentiated NPC who underwent RT.     

鼻咽癌中miR-421和FOXO4的表达及与放疗敏感性和预后的相关性

目的:研究鼻咽癌中miR-421和FOXO4的表达及与放疗敏感性和预后的相关性。方法:选择2013年1月-2015年12月期间在我院诊断为鼻咽癌并接受放疗的92例患者及同期经组织活检确诊的鼻咽部慢性炎症的50例患者,检测miR-421、FOXO4的表达量,评价鼻咽癌患者的放疗敏感性、随访鼻咽癌患者的远期生存。结果:鼻咽癌组织中FOXO4的阳性表达率明显低于鼻咽部慢性炎症组织,miR-421的表达明显高于鼻咽部慢性炎症组织;T3-4期、N2-3期、M1期、临床III-IV期鼻咽癌组织中miR-421的表达量明显高于T1-2期、N0-1期、M0期、临床I-II期鼻咽癌组织,FOXO4的阳性率明显低于T1-2期、N0-1期、M0期、临床I-II期鼻咽癌组织;放疗不敏感的鼻咽癌组织中miR-421的表达量明显高于放疗敏感的鼻咽癌组织,FOXO4的阳性率明显低于放疗敏感的鼻咽癌组织;FOXO4阳性表达的鼻咽癌患者的无进展生存期及总生存期均明显优于FOXO4阴性表达的鼻咽癌患者。结论:miR-421/FOXO4途径的改变与鼻咽癌发生、病理进程、放疗敏感性及远期预后均密切相关。     

血清VEGF-A及其受体VEGFR-2水平与鼻咽癌患者淋巴转移的关系

目的探讨鼻咽癌患者血清血管内皮生长因子-A(VEGF-A)及血管内皮生长因子受体2(VEGFR-2)水平在鼻咽癌淋巴转移中的意义。方法采用ELISA法检测68例鼻咽癌患者和20例健康对照者血清VEGF-A和VEGFR-2水平,并分析这些指标变化的意义。结果初治及复发组鼻咽癌患者血清VEGF-A、VEGFR-2水平明显高于健康对照组及完全缓解组(P均<0.05)。血清VEGF-A和VEGFR-2水平与鼻咽癌T分期及N分期均有关(P均<0.05)。有淋巴转移的鼻咽癌患者血清VEGF-A和VEGFR-2水平明显高于无淋巴转移患者(P<0.05)。32例初治鼻咽癌患者血清VEGF-A与VEGFR-2水平呈正相关(r=0.810,P<0.05)。结论高水平的血清VEGF-A、VEGFR-2在鼻咽癌发展中起重要作用,能促进鼻咽癌发生淋巴转移。     

Serum beta 2--microglobulin and carcinoembryonic antigen in patients with gastric disorders

A comparative study of carcinoembryonic antigen (CEA) and beta 2-microglobulin in serum was made by radioimmunoassay in 121 patients with gastric disease. There was no statistical difference in serum CEA and beta 2-microglobulin in patients with benign gastric disease, early gastric carcinoma, and advanced gastric carcinoma. However, CEA levels in patients with advanced gastric carcinoma were higher than those in benign gastric disease and in early gastric carcinoma but beta 2-microglobulin did not show and differences. Furthermore, after total removal of the tumor, the elevated CEA levels decreased but beta 2-microglobulin remained unchanged. We concluded that CEA appeared to predict tumor behavior more accurately in patients with gastric carcinoma than beta 2-microglobulin.     

Identification of patients with nasopharyngeal carcinoma by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Background

As diagnosis of nasopharyngeal carcinoma at an early disease stage is important, we attempted to distinguish between patients with nasopharyngeal carcinoma and noncancer controls by using serum protein profiles.

Methods

Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and CM10 protein chip were used to detect the serum proteomic patterns of 65 patients with nasopharyngeal carcinoma before radiotherapy and 93 noncancer controls. Proteomic spectra of serum samples from 50 nasopharyngeal carcinoma patients and 60 noncancer controls were used as a training set. The validity of the classification tree was then challenged with a blind test set which included another 15 patients with nasopharyngeal carcinoma and 33 noncancer controls. Biomarker Wizard 3.01 and Biomarker Pattern 5.01 were used in combination to analyze the data and to develop diagnostic models.

Results

21 protein peaks were significantly different between nasopharyngeal carcinoma and controls. 4 mass peaks (M4182, M5343, M5913 and M8702 mass/charge ratio) were chosen automatically to construct a classification tree. The classification tree correctly determined 93.8 % (45/48) of the test samples with 93.3 % (14/15) of the nasopharyngeal carcinoma samples and 93.9 % (31/33) of the noncancer samples. Using a combination of serum protein profiles and Epstein?Barr viral capsid antigen immunoglobulin A antibody tests, the diagnostic sensitivity and specificity were increased to 100 and 97 %, respectively.

Conclusions

Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry could correctly distinguish nasopharyngeal carcinoma from noncancer individuals and showed great potential for the development of a screening test for the detection of nasopharyngeal carcinoma.     

TMT定量蛋白质组学方法筛选鼻咽癌复发相关表达蛋白

目的 筛选鼻咽癌复发与正常复查随访患者血清差异表达蛋白,寻找鼻咽癌复发诊断的标志物。方法 采集复发20例和正常复查随访20例鼻咽癌患者血清,采用TMT联合二维质谱筛选差异蛋白。进一步收集新标本并采用酶联免疫吸附法（enzyme-linked immunosorbent assay,ELISA）验证差异蛋白,其中复发40例和正常复查随访41例。结果 血清中共鉴定出635个蛋白,其中可定量蛋白为413个。两次生物学重复实验中,复发组均表现下调的蛋白有41个,均表现为上调的蛋白有18个。血清ELISA验证结果发现,复发组A2M蛋白浓度较正常复查随访组低（Z=-3.177,P=0.001）。复发组40例患者中可测出A2M蛋白浓度23例,正常复查随访组41例患者中可测出A2M蛋白浓度30例,Spearman相关分析结果显示,可测复发组和可测正常复查随访组患者A2M蛋白浓度与肿瘤分期（r=-0.024,P=0.866）、年龄（r=-0.087,P=0.534）均无相关性,两组患者年龄、性别及肿瘤分期等差异无统计学意义（P＞0.05）。结论 A2M蛋白可能是鼻咽癌复发诊断的潜在标志物。     

鼻咽癌组织中高表达的GSDME对TME免疫浸润和患者预后的影响

目的：探究细胞焦亡相关基因GSDME在鼻咽癌组织中的表达及其对肿瘤微环境（TME）和患者预后的影响。方法：从TCGA数据库获得548例鼻咽癌患者的基因表达数据及临床资料,运用R语言对GSDME进行差异表达分析、GO-KEGG富集分析;从人类蛋白质图谱（HPA）数据库中获取GSDME蛋白在鼻咽癌组织和相应癌旁组织中的表达数据,通过STRING数据库探究与GSDME相互作用的蛋白质网络;应用ssGSEA算法分析GSDME在鼻咽癌组织中的表达及其与24种免疫细胞浸润的相关性,运用Spearman法分析GSDME与免疫检查点分子的相关性,通过TISIDB数据库分析GSDME表达与细胞因子基因表达的相关性。单因素和多因素COX回归分析筛选预后风险因素,基于风险因素GSDME绘制预后预测列线图和校准图,根据GSDME的表达水平对鼻咽癌患者进行生存分析和风险分析。qPCR法验证中国人鼻咽癌组织中GSDME及4种趋化因子mRNA的表达。结果：数据库数据分析显示,与癌旁组织相比,鼻咽癌组织中GSDME呈高表达（P<0.01）,GO-KEGG富集分析显示GSDME参与免疫反应、细胞焦亡相关信号通路,GSDME表达与免疫细胞浸润、细胞因子及免疫检查点分子表达等相关,qPCR检查结果验证了中国人鼻咽癌组织中GSDME呈高表达。GSDME表达量、N分期和M分期是鼻咽癌患者预后的风险因素,基于风险因素建立的列线图和校正图能较好地预测鼻咽癌患者OS,鼻咽癌组织中GSDME高表达的患者预后差。结论：GSDME在鼻咽癌癌组织中呈高表达且是患者预后风险因素,基于GSDME建立的列线图预测预后效能良好;GSDME高表达与TME免疫浸润有关,其可能是免疫治疗的潜在靶点。     

鼻咽癌外周血IL-2、IL-10水平与其放化疗敏感性的相关性分析

目的 探讨鼻咽癌患者外周血清IL-2、IL-10水平与其放化疗敏感性的相关性.方法 回顾性分析60例鼻咽癌患者的临床资料.所有患者均接受PF方案(顺铂+5-氟尿嘧啶)联合放疗治疗.采用酶联免疫吸附测定法(ELISA)检测患者放化疗前后外周血清IL-2和IL-10的水平,并以同期接受体检的20例正常健康人作为对照,分析外周血清IL-2和IL-10的水平与患者生存预后的相关性.结果 鼻咽癌患者外周血清IL-2水平显著低于正常健康人,而外周血清IL-10水平则显著高于正常健康人,差异有统计学意义(P＜0.05).外周血清IL-2的水平与鼻咽癌分期呈负相关,分期越早,其水平越高;外周血清IL-10的水平与鼻咽癌分期呈正相关,分期越早,其水平越低.鼻咽癌患者外周血清IL-2的水平越高,其CBR越高;鼻咽癌患者外周血清IL-10的水平越高,则其CBR越低.鼻咽癌患者放化疗前外周血清IL-2的水平越高,其治疗后1、3、5年的生存率越高;鼻咽癌患者放化疗前外周血清IL-10的水平越高,其治疗后1、3、5年的生存率越低.结论 IL-2和IL-10在鼻咽癌的发生、发展中发挥着重要的作用,且放化疗前患者外周血清IL-2、IL-10水平与其生存预后有着密切的联系.     

无鼻咽部症状的鼻咽癌患者颈淋巴结转移49例误诊分析

目的 :探讨无鼻咽部症状的鼻咽癌患者颈淋巴结转移临床误诊原因。方法 :行细针穿刺细胞学检查淋巴结 ,纤维鼻咽镜活检病理证实鼻咽癌。结果 :鼻咽癌患者颈部淋巴结转移 4 9例 ,误诊为颈部淋巴结炎 33例 (细胞学诊断鳞状细胞癌 10例 ,腺癌 4例 ,未分化癌 16例 ,类型未定转移癌 3例 ) ;误诊为淋巴结核 13例 (细胞学诊断鳞状细胞癌 3例 ,腺癌 2例 ,未分化癌 7例 ,类型未定转移癌 1例 ;误诊为霍奇金病 3例 ,细胞学诊断未分化癌 2例 ,类型未定转移癌 1例 )。纤维鼻咽镜活检病理均为鼻咽癌。结论 :无鼻咽部症状的鼻咽癌患者颈部淋巴结肿大 ,行穿刺细胞学检查对明确诊断有指导意义     

ERCC1 mRNA 表达水平与Ⅱ期鼻咽癌顺铂同步放化疗疗效相关性的临床研究

目的：探讨鼻咽癌组织中 DNA 切除修复交叉互补基因1（ERCC1）的 mRNA 表达水平与Ⅱ期鼻咽癌顺铂同步放化疗疗效关系。方法78例初诊经鼻咽肿物活检确诊为鼻咽部低分化鳞癌的Ⅱ期鼻咽癌患者,取患者化疗前肿瘤组织通过 RT-PCR 方法检测其 ERCC1 mRNA 表达水平,患者均接受顺铂同步放化疗。通过 RECIST 11实体瘤疗效评定标准评定近期疗效,分析 ERCC1 mRNA 表达水平与近期疗效的关系。结果78例患者均可评价疗效,有效率为8974%,疾病控制率为9487%。Ⅱ期鼻咽癌组织中 ERCC1 mRNA的中位数水平为1119。化疗前Ⅱ期鼻咽癌组织中 ERCC1 mRNA 的表达水平与治疗后的近期疗效有显著相关性（P ＜005）。结论 ERCC1 mRNA 表达水平对Ⅱ期鼻咽癌顺铂同步化疗疗效及预后有一定的预测价值。     

Soluble interleukin-2 receptors and other markers in primary lung cancer.

Serum levels of soluble interleukin-2 receptors (sIL-2R), carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), beta-chorionic gonadotropin (beta-HCG), pregnancy-specific glycoprotein (SP1), and beta 2-microglobulin (beta 2M) were taken in 92 patients with primary lung cancer and 43 controls. The mean value of sIL-2R in the cancer group was twice as high as that of the controls (P less than 0.001) and the highest values were observed in those with small cell carcinoma (SCC) (P less than 0.0001). Of the cancer patients, 51.1% had CEA values higher than the cutoff level of 5 ng/ml. Extended-disease patients had a higher percentage of increased CEA values than those with limited disease. Adenocarcinoma (ADCC) and SCC groups had the highest percentages of increased CEA levels. There was no significant difference between the groups for beta-HCG, AFP, SP1, and beta 2M, and intermarker correlation was not seen. The results suggest that sIL-2R and CEA may be useful in monitoring the extent of disease and possibly indicate the histologic subtype, thus having a bearing on treatment and prognosis.     

鼻咽癌组织及血清的NRSN2水平及临床意义

目的 探讨鼻咽癌组织及血清neurensin-2（NRSN2）的水平及临床意义。方法 收集本院2014年6月至2016年12月本院诊治的鼻咽癌组织及配对癌旁组织84例、术前血清标本45例及术后血清标本32例,选取同期49例健康体检者的血清作对照。采用实时荧光定量PCR（QPCR）检测癌组织和血清NRSN2水平,比较癌组织与癌旁组织及手术前后血清的NRSN2水平差异,分析鼻咽癌组织NRSN2水平与临床病理特征的关系,进一步采用受试者工作特征曲线（ROC）评价组织NRSN2水平在鼻咽癌早期诊断中的效能。结果 84例鼻咽癌组织的NRSN2水平为11.141±0.801,高于癌旁组织的1.165±0.071,45例鼻咽癌患者的血清NRSN2水平为9.208±0.841,高于49例健康体检者的1.127±0.084,差异有统计学意义（P＜0.05）;鼻咽癌血清NRSN2水平与组织NRSN2水平呈正相关（r=0.445, P=0.002）。鼻咽癌组织NRSN2水平与性别、年龄、N分期及颈部淋巴结转移无关（P＞0.05）,而与T分期、TNM分期及VCA IgA滴度有关（P＜0.05）。32例鼻咽癌患者的术前血清NRSN2水平为10.231±0.979,高于术后的6.907±0.713（P.0.05）。组织NRSN2水平诊断鼻咽癌的曲线下面积为0.954（95％CI：0.891～0.971）,最佳截断值为3.490的灵敏度和特异度分别为95.24％和100.0％。结论 鼻咽癌患者的组织和血清NRSN2水平均升高,且术后血清NRSN2水平降低,其可能参与了鼻咽癌的发生发展,对鼻咽癌的诊断及病情评估有一定价值。     

鼻咽癌围放疗期EB病毒IgA抗体水平的变化

目的:探讨鼻咽癌围放疗期EB病毒免疫球蛋白A（IgA）抗体水平变化的价值。方法:选自我院于2014年4月至2017年3月期间收治的鼻咽癌患者61例;另选自我院于2014年4月至2017年3月行EBV血清学检测的50例健康者作为对照组。空腹采集外周静脉血,分离血清,采用ELISA法测定衣壳抗原IgA（VCA-IgA）和早期抗原IgA（EA-IgA）水平。比较两组VCA-IgA和EA-IgA抗体水平,鼻咽癌患者放疗前后VCA-IgA和EA-IgA抗体水平和阳性率,及VCA-IgA和EA-IgA联合诊断灵敏度和特异度。结果:观察组VCA-IgA和EA-IgA抗体水平高于对照组,且有统计学差异（P<0.05）;鼻咽癌患者放疗后VCA-IgA和EA-IgA抗体水平低于放疗前,且有统计学差异（P<0.05）;鼻咽癌患者放疗后VCA-IgA和EA-IgA阳性率低于放疗前,且有统计学差异（P<0.05）;鼻咽癌患者VCA-IgA和EA-IgA联合诊断灵敏度和特异度高于VCA-IgA和EA-IgA单项诊断。结论:VCA-IgA和EA-IgA用于鼻咽癌患者治疗效果评估具有重要价值,且联合诊断灵敏度和特异度较高,具有重要研究意义。     

Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease

Plasma levels of beta-2 microglobulin (beta2M), a subunit of the human leukocyte antigen-class I (HLA-I) molecule, correlate negatively with outcome in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). We examined the clinical relevance of soluble HLA-I (sHLA-I) levels in NHL and HD. Sera from consecutive NHL (n=65) and HD (n=37) patients were analyzed in a blinded manner. NHL and HD patients had significantly higher levels of sHLA-1 and beta2M than control subjects. In NHL patients, sHLA-I levels correlated with clinical behavior in a fashion similar to that of beta2M. However, multivariate analysis incorporating beta2M, sHLA-I, and international prognostic index (IPI) indicated that NHL patients with elevated (>312.6mug/100mL) sHLA-I levels had significantly shorter survival, independent of IPI score as well as beta2M. In HD patients, beta2M but not sHLA-I levels were associated with clinical behavior. These findings not only establish the role of sHLA-I as an independent tumor marker in NHL that can be used to stratify patients, but also suggest that beta2M and sHLA-I may reflect different biological processes in HD and NHL. Further studies are needed to assess whether the immunomodulatory properties of sHLA-I may be responsible for its divergence from beta2M as an indicator of clinical behavior in HD.     

血浆EBV DNA检测在鼻咽癌诊疗中的研究新进展

鼻咽癌是中国南方地区最常见的恶性肿瘤之一,其主要发病因素包括遗传易感性、饮食因素和EB病毒（Epstein-Barr vi? rus,EBV）感染。鼻咽癌患者血浆中存在持续阳性的EBV DNA,其拷贝数与肿瘤的分期相关,有效治疗后迅速下降,复发和转移时再次升高。越来越多的研究显示,血浆EBV DNA检测在鼻咽癌早期诊断和筛查、肿瘤复发和转移诊断、预后判断以及个体化治疗等方面具有较大的价值。本文就以上问题进行分析总结以供临床和未来的研究参考。      

血清胸苷激酶1水平与鼻咽癌临床病理特征的关系

目的探讨鼻咽癌患者血清中胸苷激酶1(TK-1)的表达水平与临床病理特征之间的关系。方法选择2010年5月至2013年3月收治的58例鼻咽癌患者(试验组)和40例健康人(对照组),采用免疫印迹增强化学发光法检测血清中TK-1的浓度。结果试验组患者治疗前的血清TK-1水平显著高于对照组,差异有统计学意义(P<0.05)。治疗后,试验组患者的血清TK-1水平显著低于治疗前,差异有统计学意义(P<0.05)。试验组患者治疗前的血清TK-1水平随着TNM分期的升高呈现上升趋势,Ⅲ期和Ⅳ期患者的血清TK-1水平稍高于Ⅰ期和Ⅱ期,差异无统计学意义(P>0.05)。治疗后,Ⅲ期和Ⅳ期患者的血清TK-1水平显著高于Ⅰ期和Ⅱ期,差异有统计学意义(P<0.05)。试验组患者治疗前后血清TK-1水平与淋巴结转移无关(P>0.05)。结论鼻咽癌患者血清TK-1高表达,血清TK-l水平不仅对鼻咽癌早期诊断具有重要临床意义,且对肿瘤治疗、预后和病情的评估也有较高的临床价值。     

鼻咽癌患者血清中miR-141-3p和miR-155-3p的表达水平及其临床意义

目的:探讨鼻咽癌患者血清中miR-141-3p及miR-155-3p的表达水平及临床意义.方法:选取2017年01月至2020年09月我院收治的95例鼻咽癌患者和45例健康对照组作为研究对象,采用实时荧光定量PCR法检测miR-141-3p及miR-155-3p表达水平.应用受试者工作特征(receiver opera...     

鼻咽癌患者外周血单个核细胞中P-gp和LRP的表达及其临床意义

目的通过检测鼻咽癌患者外周血单个核细胞中P-糖蛋白(P-gp)和肺耐药相关蛋白(LRP)的表达,探讨两者在鼻咽癌多药耐药中的作用及意义.方法采用流式细胞术对54例鼻咽癌患者化疗前后外周血单个核细胞中P-gp、LRP进行检测,同期选择鼻咽部非恶性肿瘤患者10例,正常健康人10例为对照组.结果 P-gp在正常人、非恶性肿瘤及鼻咽癌初治组中的表达差异无显著性,但在复发组的表达明显高于其他组,差异有显著性.LRP在初治及复发组中的表达明显高于对照组,且化疗前后差异有显著性.P-gp和LRP的表达与年龄、性别、临床分期、病理类型、淋巴结转移无显著相关.P-gp、LRP的表达与化疗疗效密切相关.结论 P-gp、LRP的表达在鼻咽癌多药耐药的产生中具有重要意义,对临床制定化疗方案具有潜在的指导意义.     

三氧化二砷对鼻咽癌放射增敏的近期疗效

[目的]探讨三氧化二砷对鼻咽癌放射增敏作用。[方法]87例T1-4N0-1期鼻咽癌病人随机分为单纯放疗组（对照组）和三氧化二砷＋放射治疗组（试验组），观察两组病人鼻咽肿瘤和颈部肿瘤消退情况，1、2年生存率及毒副反应。[结果]放射治疗40Gy时试验组和对照组的鼻咽肿瘤消退率分别为45．45％（20，44）和18．60％（8／43），差异有统计学意义（x^2=7．183，P=0．007）。两组的颈部肿瘤消退速度无统计学差异。40Gy时肿瘤消失组和残留组1、2年无病生存率分别为100％、90．9％和82．2％、69.3％，差异有统计学意义。试验组白细胞降低和恶心呕吐较对照组发生率高，但多为Ⅰ～Ⅱ度反应。其他毒副反应两组间差异无统计学意义。[结论]放疗联合三氧化二砷增敏使鼻咽肿瘤消退更快，且无严重毒副作用。     

肝细胞癌、鼻咽癌患者谷胱甘肽硫转移酶M1和T1基因型分布

目的 探讨高危区肝细胞癌和鼻咽癌患者谷胱甘肽硫转移酶M1 (GSTM1) 及T1 (GSTT1)基因多态性的分布。方法 应用PCR技术检测181例肝细胞癌、126例鼻咽癌患者和641例对照组人体GSTM1和GSTT1基因型。结果 GSTM1空白基因型(null)在肝癌组、鼻咽癌组与对照组频率分别为65.2%、61.9%和47.6%,病例组与对照组比较,差异有统计学意义（P＜0.01)。GSTT1空白基因型(null)在肝癌组、鼻咽癌组与对照组频率分别为57.5%、62.7%和43.1%,病例组与对照组比较,差异有统计学意义（P＜0.001)。结论 在肝细胞癌、鼻咽癌高发区解毒酶基因GSTM1和GSTT1呈多态性分布,二者的null基因型均增加患肝细胞癌、鼻咽癌的风险。